The purpose of this study is to determine whether the use of lower doses of busulfan and
the elimination of cyclosporine will further reduce transplant-related side effects for
patients with Fanconi Anemia (FA). Patients will undergo a transplant utilizing
mis-matched related or matched unrelated donors following a preparative regimen of
busulfan, fludarabine, anti-thymocyte globulin and cyclophosphamide.
Additional locations may be listed on ClinicalTrials.gov for NCT02143830.
Locations matching your search criteria
United States
Washington
Seattle
Fred Hutch/University of Washington/Seattle Children's Cancer ConsortiumStatus: Active
Contact: Sheri Ballard
Phone: 206-667-4222
The trial proposed is a three arm phase II treatment protocol designed to investigate the
safety and efficacy of risk-adjusted chemotherapy-based cytoreductive regimen plus a
CD34+ selected T-cell depleted peripheral blood stem cell (PBSC) stem cell transplant for
the treatment of patients with Fanconi anemia and severe hematologic disease. Candidates
for this trial will include patients with Fanconi anemia presenting with severe marrow
failure (transfusion dependent) or myelodysplastic syndrome, or acute myelogenous
leukemia for whom an allogeneic stem cell transplant is indicated.
Lead OrganizationCincinnati Children's Hospital Medical Center